RxDoctor Payments Data

Varun Chauhan, MD

Neurology · Enid, OKNPI 1669890612

Payments from drug & device makers

$3,003in general payments, 2019–2025

Across 194 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$547
  • Neurocrine Biosciences, Inc.$468
  • AbbVie$317
  • Supernus Pharmaceuticals, Inc.$291
  • Pfizer$234
  • Biogen$177
  • plus $970 from 17 others

What the payments were for

  • Food & beverage$3,003100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,003 in reported general payments places this provider in the 55th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$232,486
Medicare patients
722
Services billed
10,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate42$371,828
Nurtec OdtRimegepant Sulfate75$140,794
BetaseronInterferon Beta-1b12$118,366
Emgality PenGalcanezumab-Gnlm76$52,168
FycompaPerampanel37$39,654
Aimovig AutoinjectorErenumab-Aooe49$36,314
Lacosamide226$31,135
BriviactBrivaracetam16$23,455
Topiramate ErTopiramate22$21,302
Levetiracetam512$20,942
Clobazam84$19,525
NayzilamMidazolam27$18,124
UbrelvyUbrogepant11$15,915
QuliptaAtogepant15$14,618
EliquisApixaban12$10,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$468$371,82842 claims
PfizerNurtec Odt, Eliquis, Dilantin$234$156,470104 claims
UCB, Inc.Briviact, Nayzilam$547$41,57943 claims
Eisai Inc.Fycompa$14$39,65437 claims
AbbVieUbrelvy, Qulipta$317$30,53226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 152 neurology providers in Oklahoma.

Other neurology in Enid

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →